U.S. Paper and Forestry Products Stock News

NasdaqGS:ROCK
NasdaqGS:ROCKBuilding

Gibraltar Industries (ROCK) Valuation Check After Recent Share Price Rebound And Portfolio Refocus

Gibraltar Industries (ROCK) is back on investors’ radar after a recent share price move, with the stock closing at US$37.18 as its recent performance and fundamentals draw closer attention. See our latest analysis for Gibraltar Industries. The recent 4.61% 1 day share price return and 5.09% 7 day share price return sit against a much weaker backdrop, with the 1 year total shareholder return down 37.07% and the 5 year total shareholder return down 53.20%. This suggests that recent momentum is...
NasdaqGS:VLY
NasdaqGS:VLYBanks

How Investors Are Reacting To Valley National Bancorp (VLY) Refinancing Debt While Maintaining Its Dividend

In May 2026, Valley National Bancorp completed a US$500.00 million fixed‑to‑floating subordinated notes offering, announced the full redemption of its US$300.00 million 3.00% subordinated notes due 2031, and affirmed a quarterly common dividend of US$0.1100 per share payable on July 1, 2026. Together with board approvals, director equity grants, and a refreshed corporate social responsibility report, these capital and governance moves outline how Valley is reshaping its funding mix while...
NasdaqGS:EWBC
NasdaqGS:EWBCBanks

Does EWBC’s New Stock Plans Clarify Management’s Long‑Term Incentive Strategy or Complicate Shareholder Value?

Earlier this week, East West Bancorp filed two shelf registrations totaling US$483.76 million for ESOP-related common stock offerings and granted routine stock awards to non-employee directors following its 2026 Annual Meeting. Shareholders also endorsed all governance proposals, including refreshed stock incentive and employee stock purchase plans, signaling strong support for management’s long-term capital and compensation framework. With shareholders backing new stock plans and...
NasdaqGM:URGN
NasdaqGM:URGNBiotechs

How UGN-103’s Phase 3 Data and NDA Timeline Could Reshape UroGen Pharma (URGN) Investors’ Outlook

Earlier in May 2026, UroGen Pharma reported new Phase 3 data showing UGN-103 achieved a 94.5% six-month durability of response in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, closely mirroring outcomes seen with its approved intravesical therapy ZUSDURI. The company also highlighted long-term durability results for ZUSDURI and outlined plans to file an NDA for UGN-103 in the third quarter of 2026, aiming to expand its RTGel-based bladder cancer franchise and...
NYSE:NEXA
NYSE:NEXAMetals and Mining

Assessing Nexa Resources (NEXA) Valuation After Its Strong Multi Year Share Price Rebound

Why Nexa Resources Is On Investors’ Radar Today Nexa Resources (NEXA) stock has drawn fresh attention after a strong year to date return of 64.62%, prompting investors to reassess how its mining and smelting operations line up with current market expectations. See our latest analysis for Nexa Resources. At a share price of $14.47, Nexa Resources has seen firm momentum build over the past quarter, with a 90 day share price return of 23.57% and a 1 year total shareholder return of 194.28%...
NasdaqGM:KYMR
NasdaqGM:KYMRBiotechs

Assessing Kymera Therapeutics (KYMR) Valuation After New KT-621 Phase 1b Data Presentations

Kymera Therapeutics (KYMR) is back in focus after showcasing expanded Phase 1b data for KT-621, its oral STAT6 degrader, at major dermatology and respiratory conferences. The company highlighted clinical signals in atopic dermatitis and asthma. See our latest analysis for Kymera Therapeutics. Despite the recent KT-621 data spotlight, Kymera Therapeutics’ share price has eased in the near term, with the 30 day share price return down 7.09% and the 90 day share price return down 10.79%. At the...
NasdaqGS:VFS
NasdaqGS:VFSAuto

A Look At VinFast Auto (NasdaqGS:VFS) Valuation As Factory Sales And EV Upgrades Target Lower Debt

VinFast Auto (NasdaqGS:VFS) is back in focus after outlining plans to sell two factories in Vietnam to cut about US$6.9b of debt, alongside rolling out upgraded electric SUVs and expanding global after-sales support. See our latest analysis for VinFast Auto. The recent factory sale plan, upgraded VF 8 and VF 9 launches, and global service push arrive after a mixed run for investors. The share price is at US$3.57, with a 30 day share price return down 18.12%, a 90 day share price return up...
NasdaqGS:MAT
NasdaqGS:MATLeisure

How Investors Are Reacting To Mattel (MAT) Boosting Digital Spend While Trimming EPS Guidance

Earlier in May 2026, Mattel said it would lift spending by US$150,000,000 on mobile gaming, its Brick Shop initiative, and direct-to-consumer marketing, while simultaneously trimming its 2026 earnings-per-share guidance but committing to a US$1.50 billion share repurchase over three years. Alongside this heavier near-term investment, a cluster of routine director restricted stock unit settlements and a new Hot Wheels “Tiniest Team Principal” program highlight Mattel’s focus on both...
NYSE:TRU
NYSE:TRUProfessional Services

TransUnion (TRU) Valuation Check As Google YouTube Attribution Partnership Gains Traction

TransUnion (TRU) stock is back in focus after the company and Google introduced a new way for marketers to measure YouTube advertising within TransUnion’s Multi Touch Attribution solution, tying video ad exposure directly to business outcomes. See our latest analysis for TransUnion. At a share price of US$70.66, TransUnion’s 1-day and 7-day share price returns of 1.71% and 6.64% stand in contrast to a year-to-date share price decline of 15.20% and a 1-year total shareholder return decline of...
NasdaqGS:SKWD
NasdaqGS:SKWDInsurance

How Investors May Respond To Skyward Specialty (SKWD) Leadership Additions And Brighter Analyst Earnings Outlook

Earlier in May 2026, Skyward Specialty Insurance Group appointed industry veteran Melissa Goto as President of E&S Brokerage and Inland Marine and shareholders elected Peter C. Hearn to the board, adding deep underwriting and leadership expertise across complex specialty P&C markets. These leadership additions arrive as external analysts grow more optimistic about Skyward’s earnings outlook and its positioning in specialized commercial insurance niches. Next, we’ll explore how these analyst...
NasdaqCM:SIDU
NasdaqCM:SIDUAerospace & Defense

Sidus Space (SIDU) Valuation After Capital Raise Stronger Q1 And New Space Services Contract

Sidus Space (SIDU) is back on radar after its mid May Q1 2026 report, which showed higher year over year revenue, a smaller net loss, and confirmation of a recent US$58.5 million capital raise. See our latest analysis for Sidus Space. The earnings update and April capital raise appear to have reset expectations, with the share price returning 152.22% over 90 days and total shareholder return of 228.21% over one year, despite a weaker three year total shareholder return. If Sidus Space’s...
NasdaqCM:ATEX
NasdaqCM:ATEXTelecom

Assessing Anterix (ATEX) Valuation After Powerful Recent Share Price Momentum

Anterix (ATEX) has drawn attention after recent trading, with the stock last closing at $63.57 and showing strong short term and past 3 months moves. This has prompted investors to reassess its current pricing. See our latest analysis for Anterix. Recent momentum has been strong, with a 30 day share price return of 40.73% and a year to date share price return of 185.96%. The 1 year total shareholder return of 134.58% points to sustained interest over a longer period. If this kind of move has...
NYSE:QSR
NYSE:QSRHospitality

The Bull Case For Restaurant Brands International (QSR) Could Change Following Earnings Beat And Burger King Uptick

Restaurant Brands International recently reported earnings that exceeded expectations, supported by steadier US Burger King same-store sales, and later held a fireside chat with its executive chairman and CEO at Bernstein’s 42nd Annual Strategic Decisions Conference, with the discussion streamed via its investor relations website. The combination of earnings outperformance and attention from high-profile investor Seth Klarman, who holds the company as his largest position, has sharpened...
NasdaqGS:ONC
NasdaqGS:ONCBiotechs

Why BeOne Medicines (ONC) Is Up 5.8% After FDA Nod For BEQALZI In Mantle Cell Lymphoma

Earlier in May 2026, BeOne Medicines received U.S. FDA accelerated approval for BEQALZI (sonrotoclax), a next-generation BCL2 inhibitor for adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic therapies including a BTK inhibitor. This first U.S. approval for sonrotoclax reshapes BeOne’s oncology profile by adding a new commercial pillar alongside its BTK franchise and broad late-stage pipeline. We’ll now examine how adding BEQALZI as an approved BCL2...
NYSE:ENOV
NYSE:ENOVMedical Equipment

A Look At Enovis (ENOV) Valuation After ESOP Shelf Registration For Up To 3,650,000 Shares

Enovis (ENOV) has drawn attention after filing a US$92.16 million shelf registration to potentially issue up to 3,650,000 common shares in an employee stock ownership plan related offering. See our latest analysis for Enovis. The shelf registration and recent insider stock grants come as the share price trades at US$24.19, with a 90 day share price return of 7.89% but a 1 year total shareholder return that declined 23.35%. This indicates some recent momentum after a longer period of weaker...
NYSE:DE
NYSE:DEMachinery

Deere (DE) Is Down 5.8% After Profit Mix Shifts Away From Large Ag Equipment - Has The Bull Case Changed?

In May 2026, Deere & Company reported fiscal second-quarter results showing revenue rising to US$13.37 billion while net income eased slightly to US$1.77 billion, and reaffirmed full-year 2026 net income guidance of US$4.5 billion to US$5.0 billion. Beneath the headline beat on earnings per share, performance tilted away from large agricultural equipment toward faster-growing Construction & Forestry and Small Agriculture & Turf, highlighting how Deere’s profit mix is shifting as farm markets...
NasdaqGM:ORKA
NasdaqGM:ORKABiotechs

Encouraging ORKA-001 Psoriasis Data and Upsized Offering Could Be A Game Changer For Oruka Therapeutics (ORKA)

In May 2026, Oruka Therapeutics reported a first-quarter net loss of US$31.82 million and disclosed insider stock option exercises and share sales by Senior Vice President Arjun Agarwal under a pre-arranged Rule 10b5-1 trading plan. Ahead of this, the company announced encouraging interim Phase 2a results for its ORKA-001 plaque psoriasis candidate and priced an upsized public offering of about US$700.40 million to support its development programs. Next, we’ll examine how the positive...
NasdaqGS:KALU
NasdaqGS:KALUMetals and Mining

Should Stronger Earnings Sentiment and Insider Selling at Kaiser Aluminum (KALU) Require Action From Investors?

Kaiser Aluminum has recently benefited from stronger analyst sentiment and an improved earnings outlook, supported by industry-wide strength in aluminum amid supply disruptions and tariffs earlier this year. An interesting angle is that this improved outlook comes alongside signs of rich valuation metrics and recent insider selling, creating a complex setup for investors assessing the company’s current position. With analyst earnings expectations rising, we’ll now examine how this brighter...
NasdaqGM:STAA
NasdaqGM:STAAMedical Equipment

Assessing STAAR Surgical (STAA) Valuation After A Sharp Multi‑Month Share Price Rebound

Recent performance snapshot for STAAR Surgical STAAR Surgical (STAA) has drawn attention after a strong share price move, with the stock up about 26% over the past month and about 78% over the past 3 months. See our latest analysis for STAAR Surgical. At the current share price of US$32.47, STAAR Surgical’s recent 30 day share price return of 26.5% and 90 day share price return of 78.4% contrast with a 5 year total shareholder return that is down 77.8%, suggesting momentum has picked up after...
NasdaqGS:LITE
NasdaqGS:LITECommunications

Is Nasdaq-100 Entry And AI Data Center Momentum Altering The Investment Case For Lumentum (LITE)?

In May 2026, Lumentum Holdings Inc. was added to the Nasdaq-100 Index, coinciding with record fiscal Q3 2026 results driven by demand for its optical and photonic products in AI data centers and cloud networking. At the same time, the launch of a 2X leveraged ETF tied to Lumentum and a multi-billion-dollar NVIDIA investment underscored the company’s growing role in AI infrastructure and investor efforts to gain amplified exposure to this theme. We’ll now examine how Lumentum’s Nasdaq-100...